Meeting Banner
Abstract #0088

A T2* MRI Prospective Survey on Pancreatic Iron in Thalassemia Major Patients Treated with Deferasirox, Deferiprone and Desferrioxamine

Antonella Meloni 1 , Gennaro Restaino 2 , Stefania Renne 3 , Massimiliano Missere 2 , Maria Chiara Resta 4 , Vincenzo Positano 1 , Daniele De Marchi 1 , Gaetano Roccamo 5 , Nicola Romano 6 , Maria Giovanna Neri 1 , and Alessia Pepe 1

1 CMR Unit, Fondazione G. Monasterio CNR-Regione Toscana, Pisa, Italy, 2 Dipartimento di Radiologia, Universit Cattolica del Sacro Cuore, Campobasso, Italy, 3 Struttura Complessa di Cardioradiologia-UTIC, P.O. Giovanni Paolo II, Lamezia Terme, Italy, 4 Struttura Complessa di Radiologia, OSP. SS. Annunziata ASL Taranto, Taranto, Italy, 5 Unit di Prevenzione e Cura delle Mictrocitemie, PO di S. Agata di Militello (ASP-ME), S. Agata di Militello (ME), Italy, 6 S.C. Medicina Trasfusionale, AO Arcispedale "S. Maria Nuova", Reggio Emilia, Italy

For the first time, we described the changes in pancreatic T2* values over a follow-up (FU) of 18 months and we evaluated prospectively the effectiveness of the three iron chelators in monotherapy in thalassemia major (TM) patients. At the dosages used in the clinical practice all three chelators in monotherapy allowed a significant reduction in pancreatic iron.

This abstract and the presentation materials are available to members only; a login is required.

Join Here